Hunan Jingfeng Pharmaceutical Total Assets
Hunan Jingfeng Pharmaceutical total assets. Based on the latest financial reports, Hunan Jingfeng Pharmaceutical (000908) holds total assets worth CN¥877.99 Million CNY (≈ $128.48 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 000908 market cap for the company's overall valuation and market capitalisation.
Total Assets of Hunan Jingfeng Pharmaceutical (1995–2024)
Total assets of Hunan Jingfeng Pharmaceutical from 1995 to 2024. This chart illustrates how Hunan Jingfeng Pharmaceutical's total assets have evolved over time, based on quarterly financial data. See Hunan Jingfeng Pharmaceutical stock quote for real-time trading data and today's change.
Hunan Jingfeng Pharmaceutical - Asset Composition Analysis
Hunan Jingfeng Pharmaceutical Total Assets Breakdown (December 2024)
Hunan Jingfeng Pharmaceutical total assets breakdown as of December 2024. Hunan Jingfeng Pharmaceutical's total assets of CN¥877.99 Million consist of 24.2% current assets and 75.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.1% |
| Accounts Receivable | CN¥81.96 Million | 8.7% |
| Inventory | CN¥44.18 Million | 4.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥163.82 Million | 17.4% |
| Goodwill | CN¥116.91K | 0.0% |
Asset Composition Trend (1995–2024)
This chart illustrates how Hunan Jingfeng Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 000908 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hunan Jingfeng Pharmaceutical's current assets represent 24.2% of total assets in 2024, a decrease from 50.7% in 1995.
- Cash Position: Cash and equivalents constituted 9.1% of total assets in 2024, down from 9.2% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 4.0% in 1995.
- Asset Diversification: The largest asset category is intangible assets at 17.4% of total assets.
Hunan Jingfeng Pharmaceutical Competitors by Total Assets
Key competitors of Hunan Jingfeng Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
Novo Nordisk A/S
CO:NOVO-B
|
Denmark | Dkr542.90 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
SANOFI CONS HEALTHC IND L
NSE:SANOFICONR
|
India | Rs5.47 Billion |
Hunan Jingfeng Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.39 | 0.20 | 0.55 |
| Quick Ratio | 0.32 | 0.14 | 0.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-480.78 Million | CN¥-834.47 Million | CN¥-836.79 Million |
Hunan Jingfeng Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Hunan Jingfeng Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 157.09 |
| Latest Market Cap to Assets Ratio | 0.75 |
| Asset Growth Rate (YoY) | -11.4% |
| Total Assets | CN¥939.98 Million |
| Market Capitalization | $708.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hunan Jingfeng Pharmaceutical's assets below their book value (0.75x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hunan Jingfeng Pharmaceutical's assets decreased by 11.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hunan Jingfeng Pharmaceutical (1995–2024)
The table below shows the annual total assets of Hunan Jingfeng Pharmaceutical from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥939.98 Million ≈ $137.55 Million |
-11.35% |
| 2023-12-31 | CN¥1.06 Billion ≈ $155.16 Million |
-27.79% |
| 2022-12-31 | CN¥1.47 Billion ≈ $214.88 Million |
-18.07% |
| 2021-12-31 | CN¥1.79 Billion ≈ $262.27 Million |
-33.37% |
| 2020-12-31 | CN¥2.69 Billion ≈ $393.63 Million |
-38.16% |
| 2019-12-31 | CN¥4.35 Billion ≈ $636.55 Million |
-16.78% |
| 2018-12-31 | CN¥5.23 Billion ≈ $764.89 Million |
+7.36% |
| 2017-12-31 | CN¥4.87 Billion ≈ $712.45 Million |
-5.17% |
| 2016-12-31 | CN¥5.13 Billion ≈ $751.27 Million |
+49.13% |
| 2015-12-31 | CN¥3.44 Billion ≈ $503.77 Million |
+79.89% |
| 2014-12-31 | CN¥1.91 Billion ≈ $280.05 Million |
+468.26% |
| 2013-12-31 | CN¥336.78 Million ≈ $49.28 Million |
-9.01% |
| 2012-12-31 | CN¥370.13 Million ≈ $54.16 Million |
-12.18% |
| 2011-12-31 | CN¥421.45 Million ≈ $61.67 Million |
-10.59% |
| 2010-12-31 | CN¥471.37 Million ≈ $68.98 Million |
-39.94% |
| 2009-12-31 | CN¥784.81 Million ≈ $114.84 Million |
-20.67% |
| 2008-12-31 | CN¥989.24 Million ≈ $144.76 Million |
+21.47% |
| 2007-12-31 | CN¥814.38 Million ≈ $119.17 Million |
-0.98% |
| 2006-12-31 | CN¥822.47 Million ≈ $120.35 Million |
-2.10% |
| 2005-12-31 | CN¥840.14 Million ≈ $122.94 Million |
-5.55% |
| 2004-12-31 | CN¥889.56 Million ≈ $130.17 Million |
-9.51% |
| 2003-12-31 | CN¥983.02 Million ≈ $143.85 Million |
+13.42% |
| 2002-12-31 | CN¥866.67 Million ≈ $126.82 Million |
+39.59% |
| 2001-12-31 | CN¥620.88 Million ≈ $90.85 Million |
-11.04% |
| 2000-12-31 | CN¥697.92 Million ≈ $102.13 Million |
+0.86% |
| 1999-12-31 | CN¥691.94 Million ≈ $101.25 Million |
+46.24% |
| 1998-12-31 | CN¥473.15 Million ≈ $69.24 Million |
+257.87% |
| 1997-12-31 | CN¥132.21 Million ≈ $19.35 Million |
+0.51% |
| 1996-12-31 | CN¥131.54 Million ≈ $19.25 Million |
+98.31% |
| 1995-12-31 | CN¥66.33 Million ≈ $9.71 Million |
-- |
About Hunan Jingfeng Pharmaceutical
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the f… Read more